These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
645 related articles for article (PubMed ID: 16263158)
1. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor. Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158 [TBL] [Abstract][Full Text] [Related]
2. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945 [TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569 [TBL] [Abstract][Full Text] [Related]
4. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
5. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling. Xue A; Xue M; Jackson C; Smith RC Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of urokinase receptor increases matrix invasion without altering cell migration in a human osteosarcoma cell line. Karikó K; Kuo A; Boyd D; Okada SS; Cines DB; Barnathan ES Cancer Res; 1993 Jul; 53(13):3109-17. PubMed ID: 8391387 [TBL] [Abstract][Full Text] [Related]
7. Differential localization and expression of urokinase plasminogen activator (uPA), its receptor (uPAR), and its inhibitor (PAI-1) mRNA and protein in endometrial tissue during the menstrual cycle. Nordengren J; Pilka R; Noskova V; Ehinger A; Domanski H; Andersson C; Høyer-Hansen G; Hansson SR; Casslén B Mol Hum Reprod; 2004 Sep; 10(9):655-63. PubMed ID: 15243126 [TBL] [Abstract][Full Text] [Related]
8. Calcitonin inhibits invasion of breast cancer cells: involvement of urokinase-type plasminogen activator (uPA) and uPA receptor. Han B; Nakamura M; Zhou G; Ishii A; Nakamura A; Bai Y; Mori I; Kakudo K Int J Oncol; 2006 Apr; 28(4):807-14. PubMed ID: 16525628 [TBL] [Abstract][Full Text] [Related]
9. Posttranscriptional regulation of urokinase receptor expression by heterogeneous nuclear ribonuclear protein C. Velusamy T; Shetty P; Bhandary YP; Liu MC; Shetty S Biochemistry; 2008 Jun; 47(24):6508-17. PubMed ID: 18494499 [TBL] [Abstract][Full Text] [Related]
10. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. Gallicchio MA; Kaun C; Wojta J; Binder B; Bach LA J Cell Physiol; 2003 Oct; 197(1):131-8. PubMed ID: 12942549 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression. Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015 [TBL] [Abstract][Full Text] [Related]
12. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice. Lutz V; Reuning U; Krüger A; Luther T; von Steinburg SP; Graeff H; Schmitt M; Wilhelm OG; Magdolen V Biol Chem; 2001 May; 382(5):789-98. PubMed ID: 11517932 [TBL] [Abstract][Full Text] [Related]
13. Urokinase plasminogen activator, uPa receptor, and its inhibitor in vernal keratoconjunctivitis. Leonardi A; Brun P; Sartori MT; Cortivo R; Dedominicis C; Saggiorato G; Abatangelo G; Secchi AG Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1364-70. PubMed ID: 15790903 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of epidermal growth factor-induced invasion by dexamethasone and AP-1 decoy in human squamous cell carcinoma cell lines. Shiratsuchi T; Ishibashi H; Shirasuna K J Cell Physiol; 2002 Dec; 193(3):340-8. PubMed ID: 12384986 [TBL] [Abstract][Full Text] [Related]
16. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling. Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576 [TBL] [Abstract][Full Text] [Related]
17. A urokinase receptor mRNA binding protein-mRNA interaction regulates receptor expression and function in human pleural mesothelioma cells. Shetty S; Idell S Arch Biochem Biophys; 1998 Aug; 356(2):265-79. PubMed ID: 9705217 [TBL] [Abstract][Full Text] [Related]
18. Regulation by epidermal growth factor of human squamous cell carcinoma plasminogen activator-mediated proteolysis of extracellular matrix. Niedbala MJ; Sartorelli AC Cancer Res; 1989 Jun; 49(12):3302-9. PubMed ID: 2497975 [TBL] [Abstract][Full Text] [Related]
19. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells. Jardí M; Inglés-Esteve J; Burgal M; Azqueta C; Velasco F; López-Pedrera C; Miles LA; Félez J Thromb Haemost; 1996 Dec; 76(6):1009-19. PubMed ID: 8972026 [TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma. Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]